What is the purpose of the pre-examination staff review for sequence listings?
The pre-examination staff review at the USPTO serves a crucial role in ensuring that patent applications containing nucleotide and/or amino acid sequence disclosures comply with formal requirements before examination begins. According to MPEP 2414.01: “Initial review by the pre-examination staff at the USPTO checks for compliance with formal matters. In order to ensure that an…
Read MoreWhat happens if a patent application doesn’t meet the sequence listing requirements?
If a patent application filed on or after July 1, 2022, does not meet the sequence listing requirements, the USPTO will notify the applicant and provide a period of time to comply. This process is outlined in 37 CFR 1.835(d)(1): “If any of the requirements of §§ 1.831 through 1.834 are not satisfied in an…
Read MoreCan I amend a “Sequence Listing XML” in my patent application?
Yes, you can amend a “Sequence Listing XML” in your patent application. The process for amending a “Sequence Listing XML” due to errors or omissions is outlined in 37 CFR 1.835(b). As stated in the MPEP: “To amend a “Sequence Listing XML” due to errors or omissions, the procedure is outlined in 37 CFR 1.835(b).…
Read MoreHow do I add a “Sequence Listing XML” to my patent application?
To add a “Sequence Listing XML” to your patent application, you must follow the requirements specified in 37 CFR 1.835(a). The MPEP provides guidance on this process: “Adding a “Sequence Listing XML” where one was not previously filed must conform with the requirements of 37 CFR 1.835(a). See MPEP § 2414.02 for details.” It’s important…
Read More